Uberflip is the world’s #1 Content Experience Platform (CEP). With tools to aggregate all your marketing content, they empower B2B marketing and sales teams to create personalized content experiences to engage accounts, nurture prospects, and convert leads, without the help of IT. It’s their mission to put control back in the hands of marketing teams to deliver high-converting experiences, that put the customer front and center.

C-Suite On Deck

Randy Frisch, CMO and Co-Founder at Uberflip has led the content experience movement, prompting marketers to think beyond content creation and focus on the experience. 

Randy also co-hosts the Conex Show, a weekly podcast featuring top marketers and their strategies ...

Events

Related News

INDUSTRIAL IMPACT

MYCOWORKS SECURES STRATEGIC INVESTMENT FROM GM VENTURES TO DEVELOP FINE MYCELIUM MATERIALS FOR SUSTAINABLE AUTOMOTIVE INTERIORS

MycoWorks | October 19, 2022

news image

Biotechnology company MycoWorks announced today its newest investor GM Ventures, the investment arm of General Motors Co. and their long-term agreement to co-develop Fine Mycelium™ materials for potential use in a range of applications within automotive design. MycoWorks' collaboration with GM marks the exploration of its entry into one of the largest end-use markets for leather and demonstrates the significant opportunity to create more sustainable materials for the automotive space.<...

Read More

RESEARCH

CELYAD ONCOLOGY ANNOUNCES CLOSING OF $32.5 MILLION PRIVATE PLACEMENT WITH FORTRESS INVESTMENT GROUP AFFILIATE

Celyad Oncology SA | December 09, 2021

news image

Celyad Oncology SA, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced the closing of its previously announced private placement with an affiliate of Fortress Investment Group. The Company issued 6,500,000 ordinary shares at a price of USD 5.00 for gross proceeds of USD 32.5 million. The Company intends to use net proceeds from the private placement to fund research and developme...

Read More

CELL AND GENE THERAPY

2SEVENTY BIO ANNOUNCES EXPANDED COLLABORATION AGREEMENT WITH NOVO NORDISK TO CONTINUE DEVELOPMENT OF IN VIVO GENE EDITING APPROACH

2seventy bio, Inc | January 07, 2022

news image

2seventy bio, Inc. announced that it has entered into an option and license agreement with Novo Nordisk for joint research and development of an in vivo gene editing treatment for hemophilia A. This agreement builds upon a successful existing multi-year research collaboration between the two companies. Under the terms of this agreement, Novo Nordisk will have the option to license 2seventy bio’s proprietary mRNA-based megaTAL™ technology for the development of a new treatment approac...

Read More

MEDTECH

FDA GRANTS ILIAD BIOTECHNOLOGIES FAST TRACK DESIGNATION FOR NEXT GENERATION PERTUSSIS VACCINE BPZE1

ILiAD Biotechnologies | January 04, 2022

news image

ILiAD Biotechnologies, a late stage biotech development company focused on global eradication of disease due to Bordetella pertussis, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BPZE1, a next generation vaccine for active booster immunization against pertussis. BPZE1 is the most advanced next generation pertussis vaccine currently in clinical development. Developed in the laboratory of Camille Locht, PhD, at the Institut Pasteur...

Read More
news image

INDUSTRIAL IMPACT

MYCOWORKS SECURES STRATEGIC INVESTMENT FROM GM VENTURES TO DEVELOP FINE MYCELIUM MATERIALS FOR SUSTAINABLE AUTOMOTIVE INTERIORS

MycoWorks | October 19, 2022

Biotechnology company MycoWorks announced today its newest investor GM Ventures, the investment arm of General Motors Co. and their long-term agreement to co-develop Fine Mycelium™ materials for potential use in a range of applications within automotive design. MycoWorks' collaboration with GM marks the exploration of its entry into one of the largest end-use markets for leather and demonstrates the significant opportunity to create more sustainable materials for the automotive space.<...

Read More
news image

RESEARCH

CELYAD ONCOLOGY ANNOUNCES CLOSING OF $32.5 MILLION PRIVATE PLACEMENT WITH FORTRESS INVESTMENT GROUP AFFILIATE

Celyad Oncology SA | December 09, 2021

Celyad Oncology SA, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced the closing of its previously announced private placement with an affiliate of Fortress Investment Group. The Company issued 6,500,000 ordinary shares at a price of USD 5.00 for gross proceeds of USD 32.5 million. The Company intends to use net proceeds from the private placement to fund research and developme...

Read More
news image

CELL AND GENE THERAPY

2SEVENTY BIO ANNOUNCES EXPANDED COLLABORATION AGREEMENT WITH NOVO NORDISK TO CONTINUE DEVELOPMENT OF IN VIVO GENE EDITING APPROACH

2seventy bio, Inc | January 07, 2022

2seventy bio, Inc. announced that it has entered into an option and license agreement with Novo Nordisk for joint research and development of an in vivo gene editing treatment for hemophilia A. This agreement builds upon a successful existing multi-year research collaboration between the two companies. Under the terms of this agreement, Novo Nordisk will have the option to license 2seventy bio’s proprietary mRNA-based megaTAL™ technology for the development of a new treatment approac...

Read More
news image

MEDTECH

FDA GRANTS ILIAD BIOTECHNOLOGIES FAST TRACK DESIGNATION FOR NEXT GENERATION PERTUSSIS VACCINE BPZE1

ILiAD Biotechnologies | January 04, 2022

ILiAD Biotechnologies, a late stage biotech development company focused on global eradication of disease due to Bordetella pertussis, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BPZE1, a next generation vaccine for active booster immunization against pertussis. BPZE1 is the most advanced next generation pertussis vaccine currently in clinical development. Developed in the laboratory of Camille Locht, PhD, at the Institut Pasteur...

Read More

Resources

Events

C-Suite On Deck

Randy Frisch, CMO and Co-Founder at Uberflip has led the content experience movement, prompting marketers to think beyond content creation and focus on the experience. 

Randy also co-hosts the Conex Show, a weekly podcast featuring top marketers and their strategies ...